Status: Recruiting
Use of Elranatamab in Patients With High-risk Smoldering Multiple Myeloma
This is a multicenter, single arm, open-label, Phase 2 study in high risk smoldering myeloma patients. The primary objective is to determine the efficacy of Elranatamab in patients with previously untreated high-risk SMM. The key-secondary objective is to determine the safety of Elranatamab in patients with previously untreated high-risk SMM.
Participants needed: 50
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Stichting European Myeloma NetworkUpdated: Oct 18, 2024Locations: 25
Eligibility criteria
>18 years of age [+14]
Previous therapy with any systemic therapy for multiple myeloma. [+22]